Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

02029974

Psychotropic drugs --- Psychopharmacology --- Mental illness --- Mental Disorders --- Psychotropic Drugs --- Chemotherapy --- drug therapy --- therapeutic use --- Psychiatrie --- Drugs --- Medicatie --- Geneesmiddel --- Mental illness - Chemotherapy --- Mental Disorders - drug therapy - Handbooks --- Psychotropic Drugs - therapeutic use - Handbooks

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Mental illness --- Psychopharmacology --- Human behavior --- Chemotherapy --- Research --- Methodology --- Animal models --- -Mental illness --- -Psychopharmacology --- -Behavioral pharmacology --- Drugs --- Pharmacology --- Psychotropic drugs --- Madness --- Mental diseases --- Mental disorders --- Disabilities --- Psychology, Pathological --- Mental health --- Action, Human --- Behavior, Human --- Ethology --- Human action --- Human beings --- Human biology --- Physical anthropology --- Psychology --- Social sciences --- Psychology, Comparative --- -Research --- -Methodology --- Psychotropic effects --- Behavior --- -Animal models --- Behavioral pharmacology --- Chemotherapy&delete& --- Research&delete& --- Animal psychopathology --- Comparative psychiatry --- Animal models in research --- Mental illness - Chemotherapy - Research - Methodology --- Mental illness - Animal models --- Psychopharmacology - Research - Methodology --- Human behavior - Animal models

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.

Glutamic Acid -- Therapeutic use. --- Mental Disorders -- Drug therapy. --- Mental illness -- Chemotherapy. --- Mental illness -- Treatment. --- Psychopharmacology --- Glutamic acid --- Neuropsychiatry --- Glutamic Acid --- Excitatory Amino Acid Agents --- Psychiatry and Psychology --- Therapeutics --- Neurotransmitter Agents --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Amino Acids, Acidic --- Amino Acids, Dicarboxylic --- Drug Therapy --- Excitatory Amino Acid Antagonists --- Glutamates --- Mental Disorders --- Amino Acids --- Molecular Mechanisms of Pharmacological Action --- Physiological Effects of Drugs --- Pharmacologic Actions --- Amino Acids, Peptides, and Proteins --- Chemicals and Drugs --- Chemical Actions and Uses --- Health & Biological Sciences --- Psychiatry --- Pharmacy, Therapeutics, & Pharmacology --- Psychopharmacotherapy --- Glutamic acid. --- Neuropsychiatry. --- Behavioral neurology --- Glutamate --- Medicine. --- Neurosciences. --- Pharmacology. --- Psychiatry. --- Psychopharmacology. --- Medicine & Public Health. --- Pharmacology/Toxicology. --- Biological psychiatry --- Neurology --- Excitatory amino acids --- Umami (Taste) --- Toxicology. --- Behavioral pharmacology --- Drugs --- Chemotherapy --- Pharmacology --- Psychotropic drugs --- Neural sciences --- Neurological sciences --- Neuroscience --- Medical sciences --- Nervous system --- Medicine and psychology --- Mental health --- Psychology, Pathological --- Chemicals --- Medicine --- Poisoning --- Poisons --- Psychotropic effects --- Toxicology --- Drug effects --- Medical pharmacology --- Pharmacy --- Physiological effect